Opendata, web and dolomites

HifLICs SIGNED

Acute Myeloid Leukemia Leukemic Initiating Cells: Contribution of hypoxia/HIF pathway to chemoresistance and relapse

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HifLICs project word cloud

Explore the words cloud of the HifLICs project. It provides you a very rough idea of what is the project "HifLICs" about.

pointing    acute    heterogeneous    genetic    empowering    scientific    group    aml    independent    stage    regulators    practical    resistant    broad    progenitor    bone    dormant    transcription    clinical    benefit    me    genes    types    controversial    susceptible    myeloid    localization    metabolically    classified    tumors    techniques    chemotherapy    alterations    drugs    marrow    hematopoietic    lics    transcriptional    suggested    hifs    tumor    suppressor    thought    technologies    patient    cellular    pathogenesis    genotoxic    hypoxic    samples    subgroup    action    therapies    driving    family    cytogenetic    resistance    human    regulated    hif    molecular    criteria    cell    caused    cytotoxic    investigator    constitutes    lic    near    vs    oncogenic    solid    initiating    complementary    quite    therapeutic    date    heterogeneity    dormancy    candidate    therapy    acquired    substantial    diseases    mediates    niche    disease    relapse    treatment    supporting    diagnosis    leukemia    barrier    survive    single    cells    hypoxia    inactive    inducible    extend   

Project "HifLICs" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS 

Organization address
address: CARRER MUNTANER 383 3/2
city: BARCELONA
postcode: 8021
website: www.carrerasresearch.org

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS ES (BARCELONA) coordinator 158˙121.00

Map

 Project objective

Acute myeloid leukemia (AML) is a heterogeneous group of diseases caused by acquired cytogenetic and molecular alterations in hematopoietic progenitor cells. There is a substantial need to develop new therapeutic approaches to AML; however, the genetic heterogeneity of AML constitutes a barrier for the development of targeted therapies. Leukemia relapse after treatment is most often caused by a subgroup of cells commonly referred to as leukemia initiating cells (LICs), which are resistant to chemotherapy. It is thought that this resistance is the result of several properties unique to LICs, including their dormant and metabolically inactive state, making them less susceptible to genotoxic drugs. The localization of the LICs in the hypoxic bone marrow niche has been proposed as a driving factor for dormancy. The HIF (hypoxia-inducible factor) family of transcription factors mediates cellular adaptation to hypoxia. While the role of HIFs in the pathogenesis of solid tumors is quite well established, they have only recently been suggested as key regulators of LICs in specific types of leukemia. Yet, results to date are highly controversial, with some studies supporting an oncogenic activity for HIFs and others pointing to a tumor suppressor role.

We propose a broad transcriptional study of human AML classified by cytogenetic criteria and disease stage (diagnosis vs relapse). We will focus on HIF-regulated target genes in the LIC subgroup and evaluate LIC heterogeneity using state-of-the-art single-cell technologies. Our results should extend our understanding of the ability of LICs to survive cytotoxic therapy and help to identify candidate targets for clinical application.

The use of AML patient samples and single-cell techniques included in this proposal will increase my scientific knowledge and practical experience. I will also benefit from the complementary planned activities of the action, empowering me to become an independent investigator in the near future.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HIFLICS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HIFLICS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PaSION (2018)

A longitudinal assessment of treatment experience, symptoms and potential associations with biomarkers in cancer patients undergoing immune checkpoint inhibitor therapy

Read More  

SynECS (2019)

Combining carbon nanotubes and gold nanorods to investigate the extracellular space around synapses during neuronal communication

Read More  

MAHT-FunSST (2019)

Microfluidic Approaches for High-Throughput Fungicide Screening and Sensitivity Testing

Read More